<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00243087</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000446176</org_study_id>
    <secondary_id>BOEH-BI-1216.3</secondary_id>
    <secondary_id>UNMC-16005</secondary_id>
    <nct_id>NCT00243087</nct_id>
  </id_info>
  <brief_title>Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)</brief_title>
  <official_title>An Open Phase I Single Dose Escalation Study of BI 2536 Administered Intravenously in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      RATIONALE: BI 2536 may stop the growth of cancer cells by blocking some of the enzymes needed&#xD;
      for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of BI 2536 in treating&#xD;
      patients with refractory or relapsed advanced non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of BI 2536 in patients with refractory or relapsed&#xD;
           advanced aggressive non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the safety and tolerability of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, open-label, uncontrolled, multicenter study.&#xD;
&#xD;
      Patients receive BI 2536 IV over 1 hour on day 1. Courses repeat every 21 days in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of BI 2536 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity during the first treatment course. Up to 24 patients are&#xD;
      treated at the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically until disease&#xD;
      progression or initiation of another cancer treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose as measured by CTCAE v3.0 at days 1-22 of each course</measure>
    <time_frame>up to 22 days of each course</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity as measured by CTCAE v3.0 at days 1-22 of each course</measure>
    <time_frame>up to 22 days of each course</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response by CT scan or MRI as measured by RECIST criteria on day 22 of each even numbered course</measure>
    <time_frame>day 22 of every second course</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics as measured in blood samples at days 1, 2, 3, and 8 during first course and on day 1 of each subsequent course</measure>
    <time_frame>day 22 of each course</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">41</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 2536</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced aggressive non-Hodgkin's lymphoma&#xD;
             (NHL), including any of the following subtypes:&#xD;
&#xD;
               -  B-cell NHL, including any of the following subtypes:&#xD;
&#xD;
                    -  Diffuse large B-cell lymphoma&#xD;
&#xD;
                    -  Primary mediastinal (thymic) B-cell lymphoma&#xD;
&#xD;
                    -  Intravascular large B-cell lymphoma&#xD;
&#xD;
                    -  Immunoblastic B-cell lymphoma&#xD;
&#xD;
                    -  Mantle cell lymphoma&#xD;
&#xD;
                    -  Burkitt's lymphoma&#xD;
&#xD;
                    -  Follicular grade 3b lymphoma&#xD;
&#xD;
               -  T-cell NHL, including any of the following subtypes:&#xD;
&#xD;
                    -  Anaplastic large cell lymphoma&#xD;
&#xD;
                    -  Peripheral T-cell lymphoma, not otherwise specified&#xD;
&#xD;
          -  De novo or transformed disease&#xD;
&#xD;
          -  Refractory (i.e., disease not amenable to standard therapy) or relapsed disease, as&#xD;
             evidenced by 1 of the following:&#xD;
&#xD;
               -  Refractory to OR relapsed after ≥ 1 prior combination chemotherapy regimen&#xD;
&#xD;
               -  Refractory to OR relapsed after prior CD20-based immunotherapy (for patients&#xD;
                  eligible to receive such therapy)&#xD;
&#xD;
               -  Refractory after prior high-dose chemotherapy and autologous stem cell&#xD;
                  transplantation AND ≥ 100 days post transplantation&#xD;
&#xD;
          -  At least 1 bidimensionally measurable lesion ≥ 1.5 cm by CT scan, MRI, x-ray, or&#xD;
             clinical examination&#xD;
&#xD;
          -  No active CNS lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  No known coagulopathy&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT and/or AST ≤ 2.5 times upper limit of normal (ULN) (&lt; 5 times ULN if due to&#xD;
             hepatic lymphoma)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  No serious active infection that requires IV antibiotics or antifungal or antiviral&#xD;
             agents&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double-method contraception during and for 1 year&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  No known or suspected alcohol or drug abuse&#xD;
&#xD;
          -  No sensory or motor neuropathy ≥ grade 3&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  No other life-threatening illness or organ dysfunction that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior and no concurrent immunotherapy&#xD;
&#xD;
          -  No prior allogeneic bone marrow transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior and no concurrent chemotherapy (6 weeks for nitrosoureas&#xD;
             or mitomycin)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the only site of measurable disease unless there is&#xD;
             documented disease progression after completion of radiotherapy&#xD;
&#xD;
          -  More than 8 weeks since prior and no concurrent systemic radioimmunotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior and no concurrent radiotherapy&#xD;
&#xD;
               -  Concurrent palliative radiotherapy to sites other than the only measurable target&#xD;
                  lesion allowed for symptom control provided the reason for radiotherapy does not&#xD;
                  reflect progressive disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent warfarin for therapeutic anticoagulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie M. Vose, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>October 20, 2005</study_first_submitted>
  <study_first_submitted_qc>October 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2005</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

